Unichem Laboratories Ltd Stock Analysis

BSE: 506690 | NSE: UNICHEMLAB | Pharmaceuticals & Drugs | Small Cap

BSE Share Price 01-Feb-2023 18:03
337.70 -14.00 (-3.98%)

DeciZen - Make an Informed Decision on Unichem Lab

Overall Rating

1. Quality

2. Valuation


3. Price Trend

Semi Strong

Unichem Lab Price Chart

P/E Ratio ( SA) :
Market Cap :
2,377.6 Cr.
52-wk low :
52-wk high :
Bole Toh?

1. Is Unichem Laboratories Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Unichem Laboratories Ltd is a below average quality company.

2. Is Unichem Laboratories Ltd undervalued or overvalued?

The key valuation ratios of Unichem Laboratories Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Unichem Laboratories Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Unichem Laboratories Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Unichem Lab:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Unichem Laboratories Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

ROCE % 15.9%13.7%7.2%11.4%11.2%130.8%-0.4%-3.5%1.8%-2.4%-
Value Creation Index 0.1-0.0-0.5-0.2-0.28.3-1.0-1.3-0.9-1.2-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 1,0051,0441,0911,2211,4181,2319769041,1249431,036
YoY Gr. Rt. %-3.9%4.5%11.9%16.2%-13.2%-20.8%-7.3%24.3%-16.1%-
Adj EPS 13.812.
YoY Gr. Rt. %--6.7%-44.7%71.3%8.4%2631.4%-100.4%NANA-244.9%-
BVPS (₹) 89.899.9104.3112.9124.3392.6387.6375.3382378367
Adj Net Profit 12511764.81111202,544-11.2-95.545.9-66.5-105
Cash Flow from Ops. 18086.988117141-66.3-251-41.8-32.6-158-
Debt/CF from Ops. 0000.10-00-0.40-0.8-


CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -0.7%-7.8%-1.1%-16.1%
Adj EPS -195.9%-193.5%NA-244.9%
BVPS 17.324.9-0.8-1.1
Share Price 6.1% -1.2% 26.9% 28.5%

Key Financial Parameters

Performance Ratio Colour Code Guide

Return on Equity % 16.213.6711.211.2130.7-0.4-3.61.7-2.5-4
Op. Profit Mgn % 18.317.59.713.513.62.2-4.7-9.98.5-4-4.5
Net Profit Mgn % 12.411.
Debt to Equity 0000000000.10
Working Cap Days 150171183173171200296385344445432
Cash Conv. Cycle 49597163-928113169154245339

Recent Performance Summary

No data to display

Return on Equity is Poor

Sales growth has been subdued in last 3 years 0.00%

Sales growth is not so good in last 4 quarters at 7.54%

Latest Financials - Unichem Laboratories Ltd.

Standalone Consolidated
TTM EPS (₹) -14.9 -5.2
TTM Sales (₹ Cr.) 1,036 1,320
BVPS (₹.) 367 361.5
Reserves (₹ Cr.) 2,570 2,531
P/BV 0.92 0.93
PE 0.00 0.00
From the Market
52 Week Low / High (₹) 226.00 / 467.00
All Time Low / High (₹) 1.50 / 467.00
Market Cap (₹ Cr.) 2,378
Equity (₹ Cr.) 14.1
Face Value (₹) 2
Industry PE 35.8

Management X-Ray of Unichem Lab :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Unichem Lab

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)


Unichem Laboratories Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Unichem Lab on 01-Feb-2023 18:03 is : 337.7.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Feb-2023 18:03 the market cap of Unichem Lab stood at ₹ 2,377.6.
The latest PE ratio of Unichem Lab as of 01-Feb-2023 18:03 is 0.00.
The latest PB ratio of Unichem Lab as of 01-Feb-2023 18:03 is 0.92
The 52-week high of Unichem Lab is ₹ 467.0 and the 52-week low is ₹ 226.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of Unichem Lab is ₹ 1,036 ( Cr.) .

About Unichem Laboratories Ltd

Unichem Laboratories, incorporated in 1962, is engaged in manufacturing formulations, pharmaceuticals and active pharmaceutical ingredients (APIs). The company was promoted by the late Amrut Mody, a pioneer in the Indian pharmaceuticals business.

The company offers products in therapeutic areas like gastro-intestinal, cardiovascular, diabetes, psychiatry, neurology, anti-bacterial, anti-infective and pain management, among others.

Headquartered in Mumbai, the company operates at five manufacturing locations in Roha (Maharashtra), Goa, Ghaziabad (Uttar Pradesh), Pithampur (Madhya Pradesh) and Baddi (Himachal Pradesh).

The company’s manufacturing facilities have received approval from various international agencies namely UK MHRA, MCC (South Africa), WHO (Geneva) and TGA (Australia). The manufacturing plants have also received ISO 9001:2000 and ISO 14001:2004 certifications for quality management.

Unichem also operates a research and development facility located at Jogeshwari (Mumbai). This facility conducts research in area of Novel Drug Delivery Systems (NDDS) and develops non-infringing routes for the manufacture of products directed at the regulated markets.


1944- Unichem was commissioned by Late Amrut Mody.

1952- The company forayed into exporting activities.

1953- Unichem entered into hormonal products segment. The same year it launched UNIPROGESTIN.

1962- The company collaborated with foreign entity UCB for bulk-drugs. It set up its first formulation plant at Jogeshwari. The company got listed at Bombay Stock Exchange. Unichem launched OESTROGEN and Progestin.

1963- The company entered co-marketing of formulations tie up with Uni Sankyo.

1968- Unichem set up a formulation plant at Ghaziabad.

1970- As part of back integration strategy, the company commissioned manufacturing of Anti-TB Drugs.

1972- As an acknowledgement for Late Amrut Mody’s  pioneering effort in Indian pharma industry, he was awarded Padma Bhushan.

1973- Unichem's research laboratory was recognised for Phd work by Bombay University. Unichem's R&D centre was recognised by Department of Science and Technology.

1976- The company set up a fine chemicals unit at Roha.

1978- Unichem commissioned its Roha bulk drug plant.

1979- The company received its first clearance from drug authorities for NEFEDIFINE.

1983- Unichem received the USFDA approval for hydrochlorothiazide manufactured at the Jogeshwari plant. The company introduced Anti-TB - Isoniazid, Rifampicin in white tablet form for the first time in India.

1984- UNISEARCH was established in collaboration with Upjohn. The company forayed anti-biotic segment and launched Ampoxin (Ampicillin and Cloxacillin combination).

1987- The company entered the animal health care business.

1994-1999- Unichem underwent thorough restructuring and transformation in line with future growth strategies.

1996- Two companies namely Unichem Exports and Unisearch was merged with Unichem Laboratories.

1997- The company’s formulation plant located at Goa was commissioned. It set up new corporate office set up at Unichem Bhavan Jogeshwari, Mumbai.

1998- The company’s formulations plant located at Baddi was fully operational.

1997-2000- The company implemented BaaN ERP.

1999- Unichem set up a modern multipurpose bulk drug plant located at Roha. Molecular generics division was launched.

2000- The drug major received South African Health Authority and UK MCA (MHRA) certifications for Goa and Baddi Plants

2001- Unichem set up new research and development centre at Mumbai. The same year it also set up New Biosciences R&D Centre located at Bangalore that would conduct research work in Bio-technology

2002- It formed a joint venture in UK called Niche Generics.

2002-2003- The company divested its animal healthcare division. It established subsidiaries in South Africa and Brazil. The company also undertook modernization of formulations plant located at Ghaziabad.

2004- Unichem conducted restructuring of Unisearch and launched of Unisearch CD Division.

2005- The company set up of new pharma technology development center located at Goa. Unichem Baddi Unit II plant was commissioned. It acquired API manufacturing unit at Pithampur

2006- The company received USFDA certification for the Goa Plant. It launched specialities division. In the same year it acquired 100% stake in Niche Generics, United Kingdom.

2007- Unikare division launched that catered to Dermatology and Allied therapies segment.

Future Strategies

Unichem will continue to work on the therapeutic segments and will develop cost effective processes for the existing molecules. It will also focus on develop new drug delivery systems and new products for international business.

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now